Michigan Patent of the Month – February 2024

Imagine waiting hours for a medical diagnosis, the clock ticking as anxiety builds. Traditional ELISA tests often paint this grim picture, burdened by time, cost, and bulky equipment that confines them to labs. Optofluidic Bioassay, LLC, a biotech company focused on making biomolecular analysis faster and lower-cost, has been granted a patent for a diagnostics system poised to revolutionize point-of-care testing.

Their invention tackles the shortcomings of conventional ELISA head-on. Gone are the cumbersome plates; replaced by a compact design that minimizes reagent use and boasts portability. Manual interventions are relegated to the past, with pre-filled wells streamlining the process and ensuring accuracy. Forget lengthy waits – this design optimizes flow for faster tests and higher throughput. To guarantee reliable results, an innovative optical cartridge prevents interference between tests.

These improvements translate into real benefits for both patients and healthcare providers. No more agonizing hours – diagnoses arrive in minutes, allowing for quicker treatment decisions. Reduced reagent volumes and automation shrink costs, making testing more accessible. The compact size and portability bring testing closer to patients, whether at the doctor’s office, in the field, or even at home. And most importantly, improved detection technology minimizes interference, leading to more accurate diagnoses.

This invention’s impact extends beyond traditional clinical settings. Imagine rapid on-site diagnoses for various diseases in field settings, empowering timely interventions. Environmental monitoring, food safety checks, and other applications now have access to portable and efficient testing. Even research and development benefit from high-throughput analysis, accelerating drug discovery and other efforts.

Are you developing new technology for an existing application? Did you know your development work could be eligible for the R&D Tax Credit and you can receive up to 14% back on your expenses? Even if your development isn’t successful your work may still qualify for R&D credits (i.e. you don’t need to have a patent to qualify). To find out more, please contact a Swanson Reed R&D Specialist today or check out our free online eligibility test.

Who We Are:

Swanson Reed is one of the U.S.’ largest Specialist R&D tax advisory firms. We manage all facets of the R&D tax credit program, from claim preparation and audit compliance to claim disputes.

Swanson Reed regularly hosts free webinars and provides free IRS CE and CPE credits for CPAs. For more information please visit us at www.swansonreed.com/webinars or contact your usual Swanson Reed representative.

Recent Posts